NLRP3 and Duchenne muscular dystrophy: Interestingly, a recent study has demonstrated that the glucocorticoid prednisone, the main treatment for DMD patients [61], inhibited NLRP3 expression, reduced inflammasome signaling and reduced related proinflammatory cytokines [88].